Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from DNA

3 F-Rated Stocks to Sell Now Rather Than Later

Although inflation is showing signs of cooling, it's still far from the Fed’s target, and the rate hikes shall continue. As the global economic outlook worsens, we believe fundamentally weak stocks Ginkgo Bioworks (DNA), Affirm Holdings (AFRM), and WeWork (WE), which are F-rated in our proprietary rating system, might be…

StockNews.com

Backstreet Boys strip on stage at AO Arena and prove 30 years on they've still got 'it'

The boys performed at Manchester's AO Arena last night as part of their DNA World Tour

Manchester Evening News

Selling cheese sandwiches is in our DNA

It feels like many moons ago now, but I can still remember that feeling of sheer joy, excitement and hope when walking off the stage with a scroll in my hand at the end of my Degree Graduation. Sadly, memories of the night out that followed are long

Birmingham Post

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Biotech Stocks to Take off Your Watchlist in 2022

Amid the macroeconomic issues and rampant volatility in the market, investor sentiment toward biotech stocks is declining. Many companies in this space are planning layoffs to reduce expenses. Amid the grim backdrop, we think investors should drop fundamentally weak biotech stocks Ginkgo Bioworks Holdings (DNA) and Immunic (IMUX) from their…

StockNews.com

4 Cathie Wood Stocks to Sell Now

Cathie Wood’s ETFs performed miserably this year amid a market rout caused by soaring inflation, the Fed’s aggressive rate hikes, and rising odds of a recession. More trouble awaits her hedge fund, concentrated in tech, as September job gains almost affirm another aggressive rate hike in the Fed’s next meeting.…

StockNews.com

5 Stocks to Delete From Your Watchlist in Q4

The stock market has been experiencing wild swings this year, with inflation at a multi-decade high and the Fed aggressively raising interest rates to bring it under control. Amid rising recession worries, we think fundamentally weak stocks, Advanced Micro Devices (AMD), Block (SQ), Ginkgo Bioworks (DNA), Rocket Lab USA (RKLB),…

StockNews.com

Staff shortages and underfunding behind Queensland's DNA testing scandal, union says

Questions are raised over whether staff shortages and budget pressures at Queensland's government-run forensic science laboratories drove a controversial ruling that has cast a cloud over thousands of major crime investigations.

ABC News

Read news from The Economist, FT, and more,
with one subscription

The Worst Biotech Stock to Own in September

Biotech stock Ginkgo Bioworks (DNA) has fallen more than 60% year-to-date. The company has been making some acquisitions recently to aid its growth over the next few years. However, given its weak financials and unfavorable analyst estimates, it may not be wise to invest in this stock now. Continue reading….

StockNews.com

Cathie Wood Doubled Down on This Biotech Stock, Should You?

Biotech company Ginkgo Bioworks’ (DNA) top-line growth didn’t translate into bottom-line improvement in its last quarter. The stock is currently trading approximately 84% below its 52-week high, and analysts expect the company to report significant losses in the fiscal 2022 and 2023. However, since renowned investor Cathie Wood has recently…

StockNews.com

3 Healthcare Stocks Wall Street Expects to Soar Nearly 200%

Substantial investments in R&D and growing demand for advanced drugs to treat chronic diseases should drive the healthcare industry’s growth. Moreover, amid the economy's uncertainties, the inelastic demand is expected to keep the sector resilient. Given this backdrop, Wall Street analysts expect healthcare stocks Ginkgo Bioworks (DNA), Zai Lab (ZLAB),…

StockNews.com

Virtual reality technology to showcase best of Derry history at the upcoming festival

The festival is set to get underway next week

Belfast Live

Why did Sudhir Chaudhary leave Zee?

There’s hardly a primetime show on Indian news TV that is not identified with its host. “Shouty” to “communal”, it’s not hard to predict how a show will tackle a subject if you know the host. So, it’s quite surprising for the news industry that one of the country’s “most…

Newslaundry

4 Pharmaceutical Stocks with Tremendous Growth Potential

The global pharmaceutical industry has witnessed robust growth over the past few years. The rapidly aging population and continued breakthroughs in drug development are expected to keep driving the industry’s growth. Thus, we think pharmaceutical stocks Assertio Holdings (ASRT), Bayer (BAYRY), Eagle Pharmaceuticals (EGRX), and Merck (MRK), which possess solid…

StockNews.com

TV Newsance 176: The data on job debates Studio Veers don't want you to see

The political twists and turns in Maharashtra dominated the news this week. Republic reporters chased after news, literally, while big boss Arnab Goswami had some advice on Hindutva for Shiv Sena supremo Uddhav Thackeray. As allegations of horse-trading, ED raids and even kidnapping flew thick and fast, anchors at Aaj…

Newslaundry

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Drug Manufacturers to Buy on the Pullback

The global pharmaceutical industry is expected to thrive with the lingering impact of COVID-19 and the evolving healthcare landscape. Given the industry’s solid prospects, the pullbacks in drug manufacturing stocks Merck & Co (MRK), Bristol-Myers Squibb (BMY), and Bayer Aktiengesellschaft (BAYRY) amid the broader market correction preset solid buying opportunity.…

StockNews.com

5 Outperforming Stocks Value Investors Should Add to Their Portfolios

The benchmark indices again ended in the red in the last trading session. With market volatility expected to remain, value investing is gaining traction. We think fundamentally sound stocks Tyson Foods (TSN), LyondellBasell (LYB), Takeda Pharmaceuticals (TAK), Bayer AG (BAYRY), and AutoNation (AN), which are currently trading at a discount,…

Benzinga

BofA Downgrades Ginkgo Bioworks, Cuts Price Target In Half

While Ginkgo Bioworks Holdings Inc’s (NYSE: DNA) overall first-quarter results were better than expected, revenues and active programs in its core Foundry segment fell short of estimates, according to BofA Securities.

StockNews.com

5 Beaten-Down Biotech Stocks Cathie Wood Loves

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022, supported by strong demand for healthcare and medical products and increasing investments in R&D. Given these factors, Wall…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Elanco, Ginkgo Bioworks Launch BiomEdit, Microbiome-Focused Animal Health Firm

Elanco Animal Health Incorporated (NYSE:ELAN) and Ginkgo Bioworks Holdings Inc (NYSE:DNA) have launched BiomEdit, a microbiome innovation company. BiomEdit will discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines, and microbial monitoring services for animal health. In October last year, Elanco announced its intention to carve out its microbiome platform and pipeline under the leadership…

StockNews.com

Is Ginkgo Bioworks a Buy Under $5?

Cell programming platform operator Ginkgo Bioworks (DNA) went public late last year in an SPAC merger. Since then, the stock has plummeted more than 60% in price, closing yesterday’s session at $4.13. In addition, analysts have increased their loss per share expectations for the stock for this year. So, would…

Benzinga

Ginkgo Bioworks Shares Gain As Q4 Sales, FY22 Guidance Surpass Street Expectations

Ginkgo Bioworks Holdings Inc (NYSE: DNA) reported

Benzinga

Why Ginkgo Bioworks Stock Is Rising After Hours

Ginkgo Bioworks Holdings Inc (NYSE: DNA) is trading higher in Monday's after-hours session after the company reported financial results and issued guidance above estimates.

Benzinga

Ginkgo Bioworks Adds Ultra-High-Throughput Screening Platform Via FGen Acquisition

Ginkgo Bioworks Holdings Inc (NYSE: DNA) has

StockNews.com

Should You Add Ginkgo Bioworks Holdings to Your Biotech Portfolio?

Ginkgo Bioworks (DNA) went public last September through an SPAC deal with Soaring Eagle Acquisition Corporation, a blank-check company led by former MGM CEO Harry Sloan. However, the stock has nosedived in price since its market debut. In addition, given an ongoing investigation into the company and its weak financials,…

Benzinga

Why BofA Sees 'Better Entry Point' In Ginkgo Bioworks Stock

Ginkgo Bioworks Holdings Inc (NYSE: DNA) is “at the forefront of the rising SynBio wave, a market we think holds much long-term promise,” according to BofA Securities.

1 2 3

People

Alex Scott

996 stories

Dipanjan BanchurSince

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

European Union

32,233 stories

Bharatiya Janata Party

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.